SunMax Biotechnology Co. Ltd. Statistics
SunMax Biotechnology Co. Ltd. (4728) Stock Statistics & Valuation Metrics
Total Valuation
SunMax Biotechnology Co. Ltd. has a market cap or net worth of TWD 21.27B. The enterprise value is TWD 19.83B.
- Market Cap
- TWD 21.27B
- Enterprise Value
- TWD 19.83B
Share Statistics
SunMax Biotechnology Co. Ltd. has 54,463,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 54,463,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.12%
Financial Efficiency
SunMax Biotechnology Co. Ltd.’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is 38.50%.
- Return on Equity (ROE)
- 0.45
- Return on Assets (ROA)
- 0.34
- Return on Invested Capital (ROIC)
- 38.50%
- Return on Capital Employed (ROCE)
- 0.55
- Revenue Per Employee
- 67.54M
- Profits Per Employee
- 24.19M
- Employee Count
- 30
- Asset Turnover
- 0.95
- Inventory Turnover
- 2.87
Valuation Ratios
The current PE Ratio of SunMax Biotechnology Co. Ltd. is 26.31. SunMax Biotechnology Co. Ltd.’s PEG ratio is 1.63.
- PE Ratio
- 26.31
- PS Ratio
- 9.73
- PB Ratio
- 14.92
- Price to FCF
- 24.76
- Price to Operating Cash Flow
- 22.26
- PEG Ratio
- 1.63
Income Statement
In the last 12 months, SunMax Biotechnology Co. Ltd. had revenue of 2.03B and earned 725.75M in profits. Earnings per share was 13.33.
- Revenue
- 2.03B
- Gross Profit
- 1.59B
- Operating Income
- 998.31M
- Pretax Income
- 1.01B
- Net Income
- 725.75M
- EBITDA
- 1.10B
- Earnings Per Share (EPS)
- 13.33
Cash Flow
In the last 12 months, operating cash flow was 959.28M and capital expenditures -97.03M, giving a free cash flow of 862.24M billion.
- Operating Cash Flow
- 959.28M
- Free Cash Flow
- 862.24M
- Free Cash Flow per Share
- 15.83
Dividends & Yields
SunMax Biotechnology Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of 6.07%
- Dividend Per Share
- ―
- Dividend Yield
- 6.07%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.04%
- Earnings Yield
- 3.80%
Stock Price Statistics
- Beta
- -0.04
- 52-Week Price Change
- -2.13%
- 50-Day Moving Average
- 396.12
- 200-Day Moving Average
- 386.18
- Relative Strength Index (RSI)
- 45.74
- Average Volume (3m)
- 13.39K
Important Dates
SunMax Biotechnology Co. Ltd. upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- May 15, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
SunMax Biotechnology Co. Ltd. as a current ratio of 3.89, with Debt / Equity ratio of 7.38%
- Current Ratio
- 3.89
- Quick Ratio
- 3.37
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.54
- Interest Coverage Ratio
- 204.40
Taxes
In the past 12 months, SunMax Biotechnology Co. Ltd. has paid 288.83M in taxes.
- Income Tax
- 288.83M
- Effective Tax Rate
- 0.28
Enterprise Valuation
SunMax Biotechnology Co. Ltd. EV to EBITDA ratio is 15.40, with an EV/FCF ratio of 24.39.
- EV to Sales
- 9.58
- EV to EBITDA
- 15.40
- EV to Free Cash Flow
- 24.39
- EV to Operating Cash Flow
- 21.92
Balance Sheet
SunMax Biotechnology Co. Ltd. has TWD 793.19M in cash and marketable securities with TWD 108.37M in debt, giving a net cash position of TWD 684.82M billion.
- Cash & Marketable Securities
- TWD 793.19M
- Total Debt
- TWD 108.37M
- Net Cash
- TWD 684.82M
- Net Cash Per Share
- TWD 12.57
- Tangible Book Value Per Share
- TWD 26.13
Margins
Gross margin is 77.79%, with operating margin of 57.94%, and net profit margin of 36.97%.
- Gross Margin
- 77.79%
- Operating Margin
- 57.94%
- Pretax Margin
- 51.01%
- Net Profit Margin
- 36.97%
- EBITDA Margin
- 62.22%
- EBIT Margin
- 58.28%
Analyst Forecast
The average price target for SunMax Biotechnology Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 12.50%
- EPS Growth Forecast
- 16.12%
